Drug research

Axatilimab

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as Niktimvo; SNDX-6352

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)NCT04710576	Syndax Pharmaceuticals	Phase 2	Recruiting	2023-04-07Actual
MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)NCT06132256	Syndax Pharmaceuticals	Phase 2	Active not recruiting	2026-09Estimated

Syndax PharmaceuticalsRecruitingPrimary completion: 2023-04-07 · Actual

Trial details

Syndax PharmaceuticalsActive not recruitingPrimary completion: 2026-09 · Estimated

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.